ENTRADA THERAPEUTICS INC
NASDAQ: TRDA (Entrada Therapeutics, Inc.)
Last update: 1 hour ago6.80
0.38 (5.92%)
| Previous Close | 6.42 |
| Volume | 291,808 |
| Price / Earnings (Forward) | 3.33 |
| Price / Sales | 60.63 |
| Price / Book | 1.13 |
| 52 Weeks Range |
| Profit Margin | 14.39% |
| Operating Margin (TTM) | -105.99% |
| Diluted EPS (TTM) | 0.580 |
| Quarterly Revenue Growth (YOY) | -65.20% |
| Total Debt/Equity (MRQ) | 13.66% |
| Current Ratio (MRQ) | 21.88 |
| Operating Cash Flow (TTM) | -54.55 M |
| Levered Free Cash Flow (TTM) | -65.48 M |
| Return on Assets (TTM) | 0.51% |
| Return on Equity (TTM) | 7.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Entrada Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.88 |
|
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 12.36% |
| % Held by Institutions | 80.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mpm Asset Management Llc | 30 Sep 2025 | 4,381,062 |
| 5Am Venture Management, Llc | 30 Jun 2026 | 4,056,379 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DOSHI DIPAL | - | 7.30 | -8,724 | -63,685 |
| DOWDEN NATHAN J | - | 7.30 | -2,528 | -18,454 |
| MPM BIOVENTURES 2014, L.P. | - | 7.15 | -130,741 | -932,460 |
| MPM BIOVENTURES 2018, L.P. | - | 7.15 | -130,741 | -932,460 |
| SETHURAMAN NATARAJAN | - | 7.30 | -2,079 | -15,177 |
| WENTWORTH KORY JAMES | - | 7.30 | -1,733 | -12,651 |
| Aggregate Net Quantity | -276,546 | |||
| Aggregate Net Value ($) | -1,974,887 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 7.20 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2014, L.P. | 03 Sep 2026 | Sell (-) | 32,263 | 7.17 | 231,326 | |
| MPM BIOVENTURES 2018, L.P. | 03 Sep 2026 | Sell (-) | 32,263 | 7.17 | 231,326 | |
| WENTWORTH KORY JAMES | Officer | 02 Sep 2026 | Disposed (-) | 1,733 | 7.30 | 12,651 |
| SETHURAMAN NATARAJAN | Officer | 02 Sep 2026 | Disposed (-) | 2,079 | 7.30 | 15,177 |
| DOWDEN NATHAN J | Officer | 02 Sep 2026 | Disposed (-) | 2,528 | 7.30 | 18,454 |
| DOSHI DIPAL | Officer | 02 Sep 2026 | Disposed (-) | 8,724 | 7.30 | 63,685 |
| MPM BIOVENTURES 2014, L.P. | 02 Sep 2026 | Sell (-) | 25,131 | 7.30 | 183,456 | |
| MPM BIOVENTURES 2018, L.P. | 02 Sep 2026 | Sell (-) | 25,131 | 7.30 | 183,456 | |
| MPM BIOVENTURES 2014, L.P. | 01 Sep 2026 | Sell (-) | 29,088 | 7.07 | 205,652 | |
| MPM BIOVENTURES 2018, L.P. | 01 Sep 2026 | Sell (-) | 29,088 | 7.07 | 205,652 | |
| MPM BIOVENTURES 2014, L.P. | 31 Aug 2026 | Sell (-) | 44,259 | 7.05 | 312,026 | |
| MPM BIOVENTURES 2018, L.P. | 31 Aug 2026 | Sell (-) | 44,259 | 7.05 | 312,026 | |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |